Oxalyldiaminopropionic acid ( ODAP ) is a structural analogue of the neurotransmitter glutamate found in the grass pea Lathyrus sativus . It is the neurotoxin responsible for the motor neuron degeneration syndrome lathyrism .
38-527: ODAP is found in the seeds of the legume L. sativus , a grass pea plant, in the range of .5% w/w. L. sativus can be found in areas of Southern, Central, and Eastern Europe, the Mediterranean Basin, Iraq and Afghanistan as well as areas of Asia and Africa. In some regions, including the Indian subcontinent, Bangladesh, Ethiopia and Nepal, the grass pea has become a staple food item. The plant has
76-417: A magnesium ion unless the cell is also experiencing depolarization . These differences show that agonists have unique mechanisms of action depending on the receptor activated and the response needed. The goal and process remains generally consistent however, with the primary mechanism of action requiring the binding of the agonist and the subsequent changes in conformation to cause the desired response at
114-402: A bound ligand is said to display "constitutive activity". The constitutive activity of a receptor may be blocked by an inverse agonist . The anti-obesity drugs rimonabant and taranabant are inverse agonists at the cannabinoid CB1 receptor and though they produced significant weight loss, both were withdrawn owing to a high incidence of depression and anxiety, which are believed to relate to
152-481: A disturbance in the normal functioning of these pathways. One antioxidant in the neutralizing pathway is glutathione (GSH), whose synthesis requires the sulfur-containing amino acids methionine and cysteine as precursors. It is thought that ODAP, possibly due to the induced excitotoxicity, reduces the intake of cysteine through its antiporter . This inhibits the synthesis of GSH, leading to an increased production of ROS and mitochondrial damage. Motor neurons may be
190-454: A drug is used therapeutically, it is important to understand the margin of safety that exists between the dose needed for the desired effect and the dose that produces unwanted and possibly dangerous side-effects (measured by the TD 50 , the dose that produces toxicity in 50% of individuals). This relationship, termed the therapeutic index , is defined as the ratio TD 50 : ED 50 . In general,
228-487: A high tolerance of environmental conditions which results in it being the only available food source in times of famine or drought. Following these several month droughts, neurolathyrism epidemics may occur. The last instance of such an epidemic (as of 2013) was in Ethiopia during the 1995-1997 drought during which 2000 people became permanently disabled. ODAP is an agonist of the ionotropic AMPA glutamate receptor. It
266-557: A particular structure. This has been analogously compared to how locks will only accept specifically shaped keys . When a ligand binds to a corresponding receptor, it activates or inhibits the receptor's associated biochemical pathway, which may also be highly specialised. Receptor proteins can be also classified by the property of the ligands. Such classifications include chemoreceptors , mechanoreceptors , gravitropic receptors , photoreceptors , magnetoreceptors and gasoreceptors. The structures of receptors are very diverse and include
304-415: A receptor and produce physiological responses such as change in the electrical activity of a cell . For example, GABA , an inhibitory neurotransmitter , inhibits electrical activity of neurons by binding to GABA A receptors . There are three main ways the action of the receptor can be classified: relay of signal, amplification, or integration. Relaying sends the signal onward, amplification increases
342-410: A receptor is its binding affinity, which is inversely related to the dissociation constant K d . A good fit corresponds with high affinity and low K d . The final biological response (e.g. second messenger cascade , muscle-contraction), is only achieved after a significant number of receptors are activated. Affinity is a measure of the tendency of a ligand to bind to its receptor. Efficacy
380-464: Is a locally acting feedback mechanism. The ligands for receptors are as diverse as their receptors. GPCRs (7TMs) are a particularly vast family, with at least 810 members. There are also LGICs for at least a dozen endogenous ligands, and many more receptors possible through different subunit compositions. Some common examples of ligands and receptors include: Some example ionotropic (LGIC) and metabotropic (specifically, GPCRs) receptors are shown in
418-403: Is known to cause neurolathyrism in humans, a motor neuron degenerative disease characterized by degeneration of pyramidal-tract neurons in the spinal cord and in the area of the cortex controlling the legs, resulting in lower-body paralysis. There is not one direct explanation as to how ODAP causes neurolathyrism; however, there has been evidence to support a few biological effects. One reason why
SECTION 10
#1732801741202456-411: Is referred to as its endogenous ligand. E.g. the endogenous ligand for the nicotinic acetylcholine receptor is acetylcholine , but it can also be activated by nicotine and blocked by curare . Receptors of a particular type are linked to specific cellular biochemical pathways that correspond to the signal. While numerous receptors are found in most cells, each receptor will only bind with ligands of
494-411: Is the measure of the bound ligand to activate its receptor. Not every ligand that binds to a receptor also activates that receptor. The following classes of ligands exist: Note that the idea of receptor agonism and antagonism only refers to the interaction between receptors and ligands and not to their biological effects. A receptor which is capable of producing a biological response in the absence of
532-467: The Greek αγωνιστής (agōnistēs), contestant; champion; rival < αγων (agōn), contest, combat; exertion, struggle < αγω (agō), I lead, lead towards, conduct; drive Receptors can be activated by either endogenous agonists (such as hormones and neurotransmitters ) or exogenous agonists (such as drugs ), resulting in a biological response. A physiological agonist is a substance that creates
570-428: The muscarinic acetylcholine receptor and NMDA receptor and their respective agonists. For the muscarinic acetylcholine receptor , which is a G protein-coupled receptor (GPCR), the endogenous agonist is acetylcholine . The binding of this neurotransmitter causes the conformational changes that propagate a signal into the cell. The conformational changes are the primary effect of the agonist, and are related to
608-422: The receptor theory of pharmacology stated that a drug's effect is directly proportional to the number of receptors that are occupied. Furthermore, a drug effect ceases as a drug-receptor complex dissociates. Ariëns & Stephenson introduced the terms "affinity" & "efficacy" to describe the action of ligands bound to receptors. In contrast to the accepted Occupation Theory , Rate Theory proposes that
646-545: The ER and ultimately cell death in both cases. In addition to acting as an agonist, there is evidence to show that ODAP is transported into the cell by an antiporter that simultaneously transports glutamate into the synapse. The second biological effect of ODAP is oxidative stress . Reactive oxygen species (ROS) are generated in the mitochondria during metabolism, and the body has mechanisms in place to neutralize these molecules before they cause damage. Oxidative stress results from
684-463: The L-α,β-diaminoproprionic acid during the reaction. Agonist An agonist is a chemical that activates a receptor to produce a biological response. Receptors are cellular proteins whose activation causes the cell to modify what it is currently doing. In contrast, an antagonist blocks the action of the agonist, while an inverse agonist causes an action opposite to that of the agonist. From
722-518: The NMDA receptor requires both the endogenous agonists , N-methyl-D-aspartate (NMDA) and glycine . These co-agonists are both required to induce the conformational change needed for the NMDA receptor to allow flow through the ion channel , in this case calcium. An aspect demonstrated by the NMDA receptor is that the mechanism or response of agonists can be blocked by a variety of chemical and biological factors. NMDA receptors specifically are blocked by
760-443: The activation of receptors is directly proportional to the total number of encounters of a drug with its receptors per unit time. Pharmacological activity is directly proportional to the rates of dissociation and association, not the number of receptors occupied: As a drug approaches a receptor, the receptor alters the conformation of its binding site to produce drug—receptor complex. In some receptor systems (e.g. acetylcholine at
798-415: The agonist's binding affinity and agonist efficacy . Other agonists that bind to this receptor will fall under one of the different categories of agonist mentioned above based on their specific binding affinity and efficacy. The NMDA receptor is an example of an alternate mechanism of action, as the NMDA receptor requires co-agonists for activation. Rather than simply requiring a single specific agonist,
SECTION 20
#1732801741202836-405: The cell, and include cytoplasmic receptors and nuclear receptors . A molecule that binds to a receptor is called a ligand and can be a protein, peptide (short protein), or another small molecule , such as a neurotransmitter , hormone , pharmaceutical drug, toxin, calcium ion or parts of the outside of a virus or microbe. An endogenously produced substance that binds to a particular receptor
874-411: The cell. 4 examples of intracellular LGIC are shown below: Many genetic disorders involve hereditary defects in receptor genes. Often, it is hard to determine whether the receptor is nonfunctional or the hormone is produced at decreased level; this gives rise to the "pseudo-hypo-" group of endocrine disorders , where there appears to be a decreased hormonal level while in fact it is the receptor that
912-458: The concentration of agonist needed to elicit half of the maximum biological response of the agonist. The EC 50 value is useful for comparing the potency of drugs with similar efficacies producing physiologically similar effects. The smaller the EC 50 value, the greater the potency of the agonist, the lower the concentration of drug that is required to elicit the maximum biological response. When
950-439: The cytoplasm. Since Ca is the signaling ion for the release of glutamate into the synapse, this can result in potentiation of the glutamate release cycle and the spread of excitotoxic damage to neighboring neurons. Inside the neuron, the extra Ca will leave the cytoplasm and enter either the mitochondria or the endoplasmic reticulum (ER), which can lead to the accumulation of misfolded or unfolded proteins in
988-403: The dynamic behavior of receptors have been used to gain understanding of their mechanisms of action. Ligand binding is an equilibrium process. Ligands bind to receptors and dissociate from them according to the law of mass action in the following equation, for a ligand L and receptor, R. The brackets around chemical species denote their concentrations. One measure of how well a molecule fits
1026-399: The effect of a single ligand , and integration allows the signal to be incorporated into another biochemical pathway. Receptor proteins can be classified by their location. Cell surface receptors , also known as transmembrane receptors, include ligand-gated ion channels , G protein-coupled receptors , and enzyme-linked hormone receptors . Intracellular receptors are those found inside
1064-414: The following major categories, among others: Membrane receptors may be isolated from cell membranes by complex extraction procedures using solvents , detergents , and/or affinity purification . The structures and actions of receptors may be studied by using biophysical methods such as X-ray crystallography , NMR , circular dichroism , and dual polarisation interferometry . Computer simulations of
1102-411: The formation of BIA from O-acetyl-L-serine (OAS) and isoxazolin-5-on. A ring opening leads to the formation of the short-lived intermediate 2,3-L-diaminopropanoic acid (DAPRO) which is then oxalylized by oxalyl- coenzyme A to form ODAP. ODAP can be synthesized from L-α,β-diaminopropionic acid and dimethyl oxalate at a pH of 4.5-5. Cupric oxide can be used to temporarily protect the α-NH2 group of
1140-577: The inhibition of the constitutive activity of the cannabinoid receptor. The GABA A receptor has constitutive activity and conducts some basal current in the absence of an agonist. This allows beta carboline to act as an inverse agonist and reduce the current below basal levels. Mutations in receptors that result in increased constitutive activity underlie some inherited diseases, such as precocious puberty (due to mutations in luteinizing hormone receptors) and hyperthyroidism (due to mutations in thyroid-stimulating hormone receptors). Early forms of
1178-421: The mechanism of action is not entirely clear may be because, so far, a good animal model for the effect of ODAP in humans has not been found. The LD 50 is also unknown. ODAP activates AMPA receptors which can induce excitotoxicity , or overstimulation of glutamate receptors. The release of too much glutamate, either at once or over a prolonged period of time, will lead to increased levels of Ca in
Oxalyldiaminopropionic acid - Misplaced Pages Continue
1216-550: The most sensitive to ODAP poisoning because they exhibit a greater dependency on the GSH precursor methionine. Further, L. sativus , as a food, is deficient in sulfur-containing amino acids, enhancing the receptor-level effects of ODAP on the production of GSH when ingested. In L. sativus ODAP is synthesized in the young seedlings from the precursor (β-isoxazolin-5-on-2-yl)-alanine, also known as BIA. BIA has not been detected in mature plant parts or ripening seeds. The pathway begins with
1254-518: The narrower this margin, the more likely it is that the drug will produce unwanted effects. The therapeutic index emphasizes the importance of the margin of safety, as distinct from the potency, in determining the usefulness of a drug. Receptor (biochemistry) In biochemistry and pharmacology , receptors are chemical structures, composed of protein , that receive and transduce signals that may be integrated into biological systems. These signals are typically chemical messengers which bind to
1292-472: The neuromuscular junction in smooth muscle), agonists are able to elicit maximal response at very low levels of receptor occupancy (<1%). Thus, that system has spare receptors or a receptor reserve. This arrangement produces an economy of neurotransmitter production and release. Cells can increase ( upregulate ) or decrease ( downregulate ) the number of receptors to a given hormone or neurotransmitter to alter their sensitivity to different molecules. This
1330-455: The potential to bind in different locations and in different ways depending on the type of agonist and the type of receptor. The process of binding is unique to the receptor-agonist relationship, but binding induces a conformational change and activates the receptor. This conformational change is often the result of small changes in charge or changes in protein folding when the agonist is bound. Two examples that demonstrate this process are
1368-403: The receptor. This response as discussed above can vary from allowing flow of ions to activating a GPCR and transmitting a signal into the cell . Potency is the amount of agonist needed to elicit a desired response. The potency of an agonist is inversely related to its half maximal effective concentration (EC 50 ) value. The EC 50 can be measured for a given agonist by determining
1406-449: The same bodily responses but does not bind to the same receptor. New findings that broaden the conventional definition of pharmacology demonstrate that ligands can concurrently behave as agonist and antagonists at the same receptor, depending on effector pathways or tissue type. Terms that describe this phenomenon are " functional selectivity ", "protean agonism", or selective receptor modulators . As mentioned above, agonists have
1444-601: The table below. The chief neurotransmitters are glutamate and GABA; other neurotransmitters are neuromodulatory . This list is by no means exhaustive. Enzyme linked receptors include Receptor tyrosine kinases (RTKs), serine/threonine-specific protein kinase, as in bone morphogenetic protein and guanylate cyclase, as in atrial natriuretic factor receptor. Of the RTKs, 20 classes have been identified, with 58 different RTKs as members. Some examples are shown below: Receptors may be classed based on their mechanism or on their position in
#201798